Treatment of IgA nephropathy with angiotensin converting enzyme inhibitors: design of a prospective randomized multicenter trial.

Abstract

Although several in vitro studies and clinical observations suggest that ACE-inhibitors (ACE-I) are a promising treatment for IgA nephropathy (IgAN), meta-analysis of published data is not yet conclusive. Therefore, a European double-blinded, prospective, randomized therapeutic trial was designed to evaluate ACE-I treatment benefits in young IgAN patients (<35 years old) with persistent moderate proteinuria (>1<3.5 g/day/1.73 m2) and fair renal function (creatinine clearance >50 mL/min/1.73 m2). Patients enrolled are randomly assigned to benazepril (0.2 mg/kg/day) or placebo. Patients should be enrolled within a five year recruitment period (end on December 2003) for a total duration of follow-up of six years (end on December 2004). Hypertension and some genetic, histological and immunological factors will be evaluated to clarify their eventual role in the final response to ACE-I treatment.

• Authors: R Coppo, M Chiesa, L Peruzzi, A Amore
• Journal: Journal of nephrology (J Nephrol) 2001 Nov-Dec Vol. 14 Issue 6 Pg. 447-52 ISSN: 1121-8428 [Print] Italy
• PMID: 11783600 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Benzazepines
• benazepril

Topics

• Adolescent
• Adult
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Benzazepines (therapeutic use)
• Child
• Child, Preschool
• Double-Blind Method
• Female
• Glomerulonephritis, IGA (drug therapy, urine)
• Humans
• Male
• Prospective Studies
• Proteinuria (etiology)
• Research Design